Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 9/20 | 0.60 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30319853 | 1.00 | MAT2A (0.60) | MAT2ATNKSKHKDRD1ALDH1A1 | |
| SCHEMBL31145476 | 0.86 | MAT2A (0.60) | MAT2ATNKSPARP1 | |
| SCHEMBL22093635 | 0.86 | MAT2A (0.60) | MAT2ATNKSPARP1 | |
| SCHEMBL22093620 | 0.84 | MAT2A (0.59) | MAT2ATNKSKHKDRD1PARP1 | |
| SCHEMBL31145391 | 0.84 | MAT2A (0.59) | MAT2ATNKSKHKDRD1PARP1 | |
| SCHEMBL31145580 | 0.84 | MAT2A (0.57) | MAT2ATNKSPARP1 | |
| SCHEMBL31145581 | 0.84 | MAT2A (0.57) | MAT2ATNKSPARP1 | |
| SCHEMBL22093075 | 0.84 | MAT2A (0.57) | MAT2ATNKSPARP1 | |
| SCHEMBL22093235 | 0.83 | MAT2A (0.69) | MAT2AALDH1A1LMNA | |
| SCHEMBL29570284 | 0.83 | MAT2A (0.69) | MAT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | claimed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | claimed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| CN-115867541-A | Aminopyrimidinone derivatives | 豪夫迈·罗氏有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TNKS 474/4885KHK 3355/4885 |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TNKS 474/4885KHK 3355/4885 |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TNKS 474/4885KHK 3355/4885 |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | MAT2A 4385/4885TNKS 911/4885KHK 3280/4885 |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TNKS 474/4885KHK 3355/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | MAT2A 2/4885TNKS 474/4885KHK 3355/4885 |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | MAT2A 4385/4885TNKS 911/4885KHK 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.